FREE SHIPPING over $40
OVER 9000 FIVE-STAR REVIEWS
5% OFF ALL SUBSCRIPTIONS
100% HAPPINESS GUARANTEE
Analyze Diet
0
Home / Equine Research Bank / Vaccine / The protective efficacy of a recombinant VP2-based African h...
Vaccine2002; 20(7-8); 1079-1088; doi: 10.1016/s0264-410x(01)00445-5

The protective efficacy of a recombinant VP2-based African horsesickness subunit vaccine candidate is determined by adjuvant.

Abstract: We previously demonstrated that soluble baculovirus-expressed African horsesickness virus (AHSV) serotype 5 VP2 protein (AHSV5 rVP2) elicits neutralising antibodies in guinea pigs. We have now determined the immunogenicity of soluble AHSV5 rVP2 in horses when administered in three different adjuvant types, ISA-50, aluminium phosphate and different saponin preparations. Doses of 10 and 50microg of rVP2 administered with saponin induced full protection to a lethal challenge, albeit with dose-related side effects. The results establish that soluble rVP2 is the biologically active form and that it can induce complete protection when it is delivered with saponin adjuvants. We conclude that the use of the soluble biologically active form of AHSV rVP2 and the choice of adjuvant will be crucial factors in determining efficacy, safety and the production cost of recombinant AHSV subunit vaccines.
Get Full Text
Publication Date: 2002-01-23 PubMed ID: 11803068DOI: 10.1016/s0264-410x(01)00445-5Google Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
LinkedInCopy
  • Journal Article
  • Research Support
  • Non-U.S. Gov't

Summary

This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.

The research paper studies the efficiency of a recombinant VP2-based vaccine candidate for African horsesickness. It found that the use of the vaccine with different adjuvants determines the successful outcome.

Introduction

  • The researchers have previously confirmed that an African horsesickness virus (AHSV) serotype 5 VP2 protein elicits neutralising antibodies in guinea pigs.
  • This soluble protein, expressed through baculovirus, is referred to as AHSV5 rVP2.
  • The research aims to determine the immunogenicity of soluble AHSV5 rVP2 in horses when delivered with different types of adjuvants.

Methods

  • The study uses three different types of adjuvants: ISA-50, aluminium phosphate and various saponin preparations.
  • These adjuvants are used to administer AHSV5 rVP2 in horses to measure their efficacy.
  • Doses of 10 and 50microg of rVP2 were used with saponin to assess the induced protection against a lethal challenge.

Results

  • The study found that doses of rVP2 administered with saponin were able to induce full protection against a lethal challenge, though side effects were reported that were related to the dosage.
  • This outcome establishes the biologically active form of soluble rVP2 as capable of inducing complete protection when paired with saponin adjuvants.

Conclusion

  • The research concludes that efficacy, safety, and production cost of recombinant AHSV subunit vaccines will be significantly influenced by the use of the soluble biologically active form of AHSV rVP2 and the choice of adjuvant.

Cite This Article

APA
Scanlen M, Paweska JT, Verschoor JA, van Dijk AA. (2002). The protective efficacy of a recombinant VP2-based African horsesickness subunit vaccine candidate is determined by adjuvant. Vaccine, 20(7-8), 1079-1088. https://doi.org/10.1016/s0264-410x(01)00445-5

Publication

Vaccine
ISSN: 0264-410X
NlmUniqueID: 8406899
Country: Netherlands
Language: English
Volume: 20
Issue: 7-8
Pages: 1079-1088

Researcher Affiliations

Scanlen, M
  • Onderstepoort Veterinary Institute, 0110, Onderstepoort, South Africa.
Paweska, J T
    Verschoor, J A
      van Dijk, A A

        MeSH Terms

        • Adjuvants, Immunologic / pharmacology
        • African Horse Sickness Virus / immunology
        • Animals
        • Capsid / immunology
        • Capsid Proteins
        • Horses
        • Immunization
        • Saponins / adverse effects
        • Saponins / pharmacology
        • Vaccines, Subunit / immunology
        • Vaccines, Synthetic / immunology
        • Viral Vaccines / immunology

        Citations

        This article has been cited 27 times.
        1. Moore S, Jukes M. The History of Baculovirology in Africa. Viruses 2023 Jul 7;15(7).
          doi: 10.3390/v15071519pubmed: 37515205google scholar: lookup
        2. Carnet F, Perrin-Cocon L, Paillot R, Lotteau V, Pronost S, Vidalain PO. An inventory of adjuvants used for vaccination in horses: the past, the present and the future. Vet Res 2023 Mar 2;54(1):18.
          doi: 10.1186/s13567-023-01151-3pubmed: 36864517google scholar: lookup
        3. Guo Z, Jia Y, Huang C, Zhou Y, Chen X, Yin R, Guo Y, Wang L, Yuan J, Wang J, Yan P, Yin R. Immunogenicity and protection against Glaesserella parasuis serotype 13 infection after vaccination with recombinant protein LolA in mice. J Vet Med Sci 2022 Nov 14;84(11):1527-1535.
          doi: 10.1292/jvms.22-0203pubmed: 36216558google scholar: lookup
        4. Fairbanks EL, Brennan ML, Mertens PPC, Tildesley MJ, Daly JM. Re-parameterization of a mathematical model of African horse sickness virus using data from a systematic literature search. Transbound Emerg Dis 2022 Jul;69(4):e671-e681.
          doi: 10.1111/tbed.14420pubmed: 34921513google scholar: lookup
        5. Sullivan E, Lecollinet S, Kerviel A, Hue E, Pronost S, Beck C, Dumarest M, Zientara S, Roy P. Entry-competent-replication-abortive African horse sickness virus strains elicit robust immunity in ponies against all serotypes. Vaccine 2021 May 27;39(23):3161-3168.
          doi: 10.1016/j.vaccine.2021.04.034pubmed: 33958224google scholar: lookup
        6. Castillo-Olivares J. African horse sickness in Thailand: Challenges of controlling an outbreak by vaccination. Equine Vet J 2021 Jan;53(1):9-14.
          doi: 10.1111/evj.13353pubmed: 33007121google scholar: lookup
        7. Calvo-Pinilla E, Marín-López A, Utrilla-Trigo S, Jiménez-Cabello L, Ortego J. Reverse genetics approaches: a novel strategy for African horse sickness virus vaccine design. Curr Opin Virol 2020 Oct;44:49-56.
          doi: 10.1016/j.coviro.2020.06.003pubmed: 32659516google scholar: lookup
        8. Rutkowska DA, Mokoena NB, Tsekoa TL, Dibakwane VS, O'Kennedy MM. Plant-produced chimeric virus-like particles - a new generation vaccine against African horse sickness. BMC Vet Res 2019 Dec 3;15(1):432.
          doi: 10.1186/s12917-019-2184-2pubmed: 31796116google scholar: lookup
        9. Porphyre T, Grewar JD. Assessing the potential of plains zebra to maintain African horse sickness in the Western Cape Province, South Africa. PLoS One 2019;14(10):e0222366.
          doi: 10.1371/journal.pone.0222366pubmed: 31671099google scholar: lookup
        10. Dennis SJ, Meyers AE, Hitzeroth II, Rybicki EP. African Horse Sickness: A Review of Current Understanding and Vaccine Development. Viruses 2019 Sep 11;11(9).
          doi: 10.3390/v11090844pubmed: 31514299google scholar: lookup
        11. Aksular M, Calvo-Pinilla E, Marín-López A, Ortego J, Chambers AC, King LA, Castillo-Olivares J. A single dose of African horse sickness virus (AHSV) VP2 based vaccines provides complete clinical protection in a mouse model. Vaccine 2018 Nov 12;36(46):7003-7010.
          doi: 10.1016/j.vaccine.2018.09.065pubmed: 30309744google scholar: lookup
        12. Lulla V, Losada A, Lecollinet S, Kerviel A, Lilin T, Sailleau C, Beck C, Zientara S, Roy P. Protective efficacy of multivalent replication-abortive vaccine strains in horses against African horse sickness virus challenge. Vaccine 2017 Jul 24;35(33):4262-4269.
          doi: 10.1016/j.vaccine.2017.06.023pubmed: 28625521google scholar: lookup
        13. Mathebula EM, Faber FE, Van Wyngaardt W, Van Schalkwyk A, Pretorius A, Fehrsen J. B-cell epitopes of African horse sickness virus serotype 4 recognised by immune horse sera. Onderstepoort J Vet Res 2017 Feb 24;84(1):e1-e12.
          doi: 10.4102/ojvr.v84i1.1313pubmed: 28281773google scholar: lookup
        14. van Gennip RGP, van de Water SGP, Potgieter CA, van Rijn PA. Structural Protein VP2 of African Horse Sickness Virus Is Not Essential for Virus Replication In Vitro. J Virol 2017 Feb 15;91(4).
          doi: 10.1128/JVI.01328-16pubmed: 27903804google scholar: lookup
        15. Conradie AM, Stassen L, Huismans H, Potgieter CA, Theron J. Establishment of different plasmid only-based reverse genetics systems for the recovery of African horse sickness virus. Virology 2016 Dec;499:144-155.
          doi: 10.1016/j.virol.2016.07.010pubmed: 27657835google scholar: lookup
        16. Lulla V, Lulla A, Wernike K, Aebischer A, Beer M, Roy P. Assembly of Replication-Incompetent African Horse Sickness Virus Particles: Rational Design of Vaccines for All Serotypes. J Virol 2016 Aug 15;90(16):7405-7414.
          doi: 10.1128/JVI.00548-16pubmed: 27279609google scholar: lookup
        17. van de Water SG, van Gennip RG, Potgieter CA, Wright IM, van Rijn PA. VP2 Exchange and NS3/NS3a Deletion in African Horse Sickness Virus (AHSV) in Development of Disabled Infectious Single Animal Vaccine Candidates for AHSV. J Virol 2015 Sep;89(17):8764-72.
          doi: 10.1128/JVI.01052-15pubmed: 26063433google scholar: lookup
        18. Calvo-Pinilla E, de la Poza F, Gubbins S, Mertens PP, Ortego J, Castillo-Olivares J. Antiserum from mice vaccinated with modified vaccinia Ankara virus expressing African horse sickness virus (AHSV) VP2 provides protection when it is administered 48h before, or 48h after challenge. Antiviral Res 2015 Apr;116:27-33.
          doi: 10.1016/j.antiviral.2015.01.009pubmed: 25643968google scholar: lookup
        19. Kanai Y, van Rijn PA, Maris-Veldhuis M, Kaname Y, Athmaram TN, Roy P. Immunogenicity of recombinant VP2 proteins of all nine serotypes of African horse sickness virus. Vaccine 2014 Sep 3;32(39):4932-7.
          doi: 10.1016/j.vaccine.2014.07.031pubmed: 25045805google scholar: lookup
        20. Alberca B, Bachanek-Bankowska K, Cabana M, Calvo-Pinilla E, Viaplana E, Frost L, Gubbins S, Urniza A, Mertens P, Castillo-Olivares J. Vaccination of horses with a recombinant modified vaccinia Ankara virus (MVA) expressing African horse sickness (AHS) virus major capsid protein VP2 provides complete clinical protection against challenge. Vaccine 2014 Jun 17;32(29):3670-4.
          doi: 10.1016/j.vaccine.2014.04.036pubmed: 24837765google scholar: lookup
        21. de la Poza F, Calvo-Pinilla E, López-Gil E, Marín-López A, Mateos F, Castillo-Olivares J, Lorenzo G, Ortego J. Ns1 is a key protein in the vaccine composition to protect Ifnar(-/-) mice against infection with multiple serotypes of African horse sickness virus. PLoS One 2013;8(7):e70197.
          doi: 10.1371/journal.pone.0070197pubmed: 23894615google scholar: lookup
        22. Lo Iacono G, Robin CA, Newton JR, Gubbins S, Wood JL. Where are the horses? With the sheep or cows? Uncertain host location, vector-feeding preferences and the risk of African horse sickness transmission in Great Britain. J R Soc Interface 2013 Jun 6;10(83):20130194.
          doi: 10.1098/rsif.2013.0194pubmed: 23594817google scholar: lookup
        23. Jabbar TK, Calvo-Pinilla E, Mateos F, Gubbins S, Bin-Tarif A, Bachanek-Bankowska K, Alpar O, Ortego J, Takamatsu HH, Mertens PP, Castillo-Olivares J. Protection of IFNAR (-/-) mice against bluetongue virus serotype 8, by heterologous (DNA/rMVA) and homologous (rMVA/rMVA) vaccination, expressing outer-capsid protein VP2. PLoS One 2013;8(4):e60574.
          doi: 10.1371/journal.pone.0060574pubmed: 23593251google scholar: lookup
        24. Manole V, Laurinmäki P, Van Wyngaardt W, Potgieter CA, Wright IM, Venter GJ, van Dijk AA, Sewell BT, Butcher SJ. Structural insight into African horsesickness virus infection. J Virol 2012 Aug;86(15):7858-66.
          doi: 10.1128/JVI.00517-12pubmed: 22593166google scholar: lookup
        25. Backer JA, Nodelijk G. Transmission and control of African horse sickness in The Netherlands: a model analysis. PLoS One 2011;6(8):e23066.
          doi: 10.1371/journal.pone.0023066pubmed: 21850252google scholar: lookup
        26. Castillo-Olivares J, Calvo-Pinilla E, Casanova I, Bachanek-Bankowska K, Chiam R, Maan S, Nieto JM, Ortego J, Mertens PP. A modified vaccinia Ankara virus (MVA) vaccine expressing African horse sickness virus (AHSV) VP2 protects against AHSV challenge in an IFNAR -/- mouse model. PLoS One 2011 Jan 26;6(1):e16503.
          doi: 10.1371/journal.pone.0016503pubmed: 21298069google scholar: lookup
        27. O'Kennedy MM, Roth R, Ebersohn K, du Plessis LH, Mamputha S, Rutkowska DA, du Preez I, Verschoor JA, Lemmer Y. Immunogenic profile of a plant-produced nonavalent African horse sickness viral protein 2 (VP2) vaccine in IFNAR-/- mice. PLoS One 2024;19(4):e0301340.
          doi: 10.1371/journal.pone.0301340pubmed: 38625924google scholar: lookup
        Subscribe to our newsletter
        Join 99,344 horse owners like you who receive our email updates on horse health and nutrition.